Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country

References

• Al-Sayaideh A, Nimri O, Arqoub K, Al-Zaghal M, Halasa W. Cancer Incidence in Jordan-2012. Ministry of Health, Non-Communicable Diseases Directorate, Jordan Cancer Registry; 2012 Available from: http://www.moh.gov.jo/Echobusv3.0/SystemAssets/a05a084b-3781-4979-a217-2184d5d57ede.pdf. Accessed 726, 2019.
   Google Scholar
• Jordan Cancer Registry. Cancer incidence in Jordan. 2015 Available from: http://www.moh.gov.jo/Pages/viewpage.aspx?pageID=240. Accessed 705, 2019.
   Google Scholar
• Johnson E. Breast cancer racial differences before age 40-implications for screening. J Nat Med Assoc. 2002;94:149–156.
   PubMed Web of Science ®Google Scholar
• Korde LA, Partridge AH, Esser M, Lewis S, Simha J, Johnson RH. Breast cancer in young women: research priorities. A report of the young survival coalition research think tank meeting. J Adolesc Young Adult Oncol. 2015;4(1 ):34–43. doi:10.1089/jayao.2014.004926812429
   PubMed Web of Science ®Google Scholar
• Rosenberg SM, Partridge AH. Management of breast cancer in very young women. Breast. 2015;24(Suppl 2 ):S154–S158. doi:10.1016/j.breast.2015.07.03626255745
   PubMed Web of Science ®Google Scholar
• Hironaka-Mitsuhashi A, Tsuda H, Yoshida M, et al. Invasive breast cancers in adolescent and young adult women show more aggressive immune-histochemical and clinical features than those in women aged 40-44 years. Breast Cancer. 2019;26(3 ):386–396. doi:10.1007/s12282-018-00937-030539373
   PubMed Web of Science ®Google Scholar
• Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20 ):3324–3330. doi:10.1200/JCO.2007.14.247118612148
   PubMed Web of Science ®Google Scholar
• Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131(3 ):1061–1066. doi:10.1007/s10549-011-1872-922080245
   PubMed Web of Science ®Google Scholar
• Hartley MC, McKinley BP, Rogers EA, et al. Differential expression of prognostic factors and effect on survival in young (< or =40) breast cancer patients: a case-control study. Am Surg. 2006;72(12 ):1189–1194.17216817
   PubMed Web of Science ®Google Scholar
• Fernandes-Taylor S, Adesoye T, Bloom JR. Managing psychosocial issues faced by young women with breast cancer at the time of diagnosis and during active treatment. Curr Opin Support Palliat Care. 2015;9(3 ):279–284. doi:10.1097/SPC.000000000000016126164840
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11 ):1329–1333. doi:10.1200/JCO.2006.09.106617416853
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Peock S, Frost D, et al. EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11 ):812–822. doi:10.1093/jnci/djt09523628597
   PubMedGoogle Scholar
• Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018;18(1 ):152. doi:10.1186/s12885-018-4079-129409476
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Marei L, Saadeh SS, et al. From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer. Breast Cancer Res Treat. 2017;165(3 ):771–777. doi:10.1007/s10549-017-4359-528667456
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Saadeh SS, Abu-Nasser M, et al. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 2018;11:2091–2096. doi:10.2147/OTT29695917
   PubMed Web of Science ®Google Scholar
• Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92:2523–2528. doi:10.1002/(ISSN)1097-014211745185
   PubMed Web of Science ®Google Scholar
• Noone AM, Cronin KA, Altekruse SF, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017;26:632–641. doi:10.1158/1055-9965.EPI-16-052027956436
   PubMed Web of Science ®Google Scholar
• Sjögren S, Inganäs M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462–469. doi:10.1200/JCO.1998.16.2.4629469329
   PubMed Web of Science ®Google Scholar
• Sheridan W, Scott T, Caroline S, et al. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time? Breast Cancer Res Treat. 2014;147(3 ):617–629. doi:10.1007/s10549-014-3125-125209005
   PubMed Web of Science ®Google Scholar
• Ribnikar D, Ribeiro JM, Pinto D, et al. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015;16(4 ):16. doi:10.1007/s11864-015-0334-825796377
   PubMed Web of Science ®Google Scholar
• Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M. Clinicopathological features of young patients (< 35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study. Breast Cancer. 2014;21(6 ):643–650. doi:10.1007/s12282-013-0466-223588791
   PubMed Web of Science ®Google Scholar
• Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (< 35 years) with operable breast cancer. Ann Oncol. 2010;21(10 ):1974–1981. doi:10.1093/annonc/mdq07220332136
   PubMed Web of Science ®Google Scholar
• Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (< 35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011;35(6 ):1244–1253. doi:10.1007/s00268-011-1071-121472372
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol. 2015;27:98–107. doi:10.1097/GCO.000000000000013825490381
   PubMed Web of Science ®Google Scholar
• Menen R, Hunt K. Considerations for the treatment of young patients with breast cancer. Breast J. 2016;22(6 ):667–672. doi:10.1111/tbj.2016.22.issue-627542172
   PubMed Web of Science ®Google Scholar